Instructions for authors
| Journal of Clinical Pharmacology & Pharmacoepidemiology ISSN (electronic): 1916-694X |
This is a peer-reviewed, open-access Journal that started to be published electronically by
PremiumReasons this year, 2010.
The Journal welcomes all the spectrum of clinical and epidemiological studies related to drug
development, from phase I to IV, including drug-drug interaction, pharmacokinetic, dose-response,
dose-finding, dose-minimization evaluations, and pharmacoeconomic studies, systematic reviews, meta-
analyses and pharmacovigilance.
Case reports are considered for publication if there is a clear novel contribution to the diagnosis or
treatment of an adverse drug reaction or acute poisoning. Any case report or observational study
reporting maternal and fetal outcomes after first-time unintended exposure to a drug in pregnancy are
welcome. The authors are responsible to present the case report in a form that identification of the
patients is impossible. If authors intend to publish a picture where a patient can be identified, written
informed consent should be obtained from the patient, parents or custodian; its submission to the
journal should also be authorized by the IRB from the center where the case was identified. These forms
should be scanned and attached to the submission of the case report.
The Journal will also consider for publication manuscripts devoted to the analysis of philosophical,
ethical or social aspects of drug research in humans. Only invited review articles will be accepted.
However, authors spontaneously wishing to submit a review paper should first submit an abstract for
consideration.
Letters to the Editor will be accepted for publication when discussing any of the papers previously
published by the Journal in a time not longer than two past issues. A request for reply will be sent to the
authors of the original article. The acceptance of the letter, however, will not be subordinated to the
availability of the authors’ reply.
Research letters containing very preliminary or specific but relevant information in the field of clinical
pharmacology, will be peer reviewed and considered for publication.
Studies should follow local and international norms for the ethical conduct of the clinical trials and be
approved in advance by an IRB. It is unacceptable to submit false studies, duplicated material, or
altered findings. Inclusion of authors who did not participate in the study should be avoided. If any of
the above misconducts are identified by a member of the scientific community and are reported to the
Journal with enough evidence, the Editor will publish in the Journal the details of the authors and the
manuscript involved in the fraudulent submission.
Since the entire submission process is electronic, avoid any postal submission except if the Journal
asks you for a specific document. Authors should adhere to the instructions described below, adapting
the use of headings and subheadings in accordance with submitted papers.
Manuscripts must include a submission letter signed by the corresponding author who declares that the
manuscript has been read and approved by all authors involved in the study; that it has not been
previously published, nor is under consideration elsewhere for publication; and that all the authors have
contributed enough to be considered as coauthors (if more than one author is listed). Grants or sources
of funding as well as any potential conflict of interest should be mentioned in the submission letter.
The submission letter must be scanned and formatted into PDF file format with the signature of the
corresponding author clearly visible. Failure to comply with these requirements may result in the delay
of the review process.
The authors need to provide a signed Copyright Transfer Agreement. The form will be e-mailed to the
corresponding authors together with the acceptance of the manuscript.
The full version of the manuscripts published by the Journal of Clinical Pharmacology &
Pharmacoepidemiology will be available at no cost for academic, personal use. However, the copyright
of all the content will retained by PremiumReasons and authors or any other person interested in further
reproducing the material for commercial or noncommercial use or public dissemination should request
written permission from the publishers (publisher@premiumreasons.com).
Papers will be published in either British or American English.
ABSTRACT. The abstract should be structured into Objectives, Material & Methods, Results, and
Conclusions. The maximum length is 250 words. None or only a minimum of abbreviations should be
used in the abstract. The P values should be preceded by data; use exact P number unless P < 0.001.
Conclusions should be based on the study findings, not on speculations. In order to extend the diffusion
of the manuscripts, abstracts will be published in two more languages, French and Spanish.
KEY WORDS: 3-6 key words should be provided. Use only MeSH terms accepted by the National Library
of Medicine (available through PubMed). If the manuscript contains uncorroborated terms as key words,
the manuscript will be returned to the authors for
correction.
INTRODUCTION: The introduction must be concise but informative, clearly identifying the gap of
knowledge and the aim of the study. All references mentioned in the text must appear in brackets [1]. If
there are several references supporting one comment, only the first and last consecutive numbers
should be written [Example: 2-4]. A maximum of 30 references is permitted for any submitted paper.
Exceptions will be made for review articles or if there is a clear justification for additional references.
SUBJECTS AND METHODS: The first paragraph of this section must specify that the study was
approved by an institutional review board as well as the site where the study was actually performed.
Use the following subheadings: Subjects, Methods, Data analysis. When describing a method that was
previously published elsewhere, cite only the main details of the procedure and include the reference
where the method was described in detail. If a complex or uncommon statistical analysis was
performed, an annotation of the software used or a reference must be provided. For standard statistical
tests do not include any additional description or reference. If the authors are including a set of
equations to support the pharmacological explanation, only the final equation should be included in this
section and the full mathematical model should be submitted as an Appendix.
RESULTS: Authors are encouraged to use text and tables to better present their results. Tables should
be progressively numbered and cited in the results (Table 1). They should be included at the end of the
manuscript following the instructions mentioned below. For values > 1, use only one decimal value, e.g.
1.8, 46.2, 198.5. For values < 1, use two significant decimal values, e.g. 0.76, 0.089, 0.0055. However,
extremely low or extremely high values should be avoided. Instead, data should be expressed in a
different unit. For example, if the mean value is 0.0087 mg dL-1, the value should be better expressed as
8.7 µg dL-1. Similarly, use 87 mg dL-1 instead of 87,000 µg dL-1.
Box plots, when applicable, are preferred over standard figures. However, tables are preferred over
figures. The figures should be submitted as separate files. Image resolutions should be: Line Art (tif or
eps) 800 dpi, Combination (Line Art + Halftone) (tif) 600 dpi, Halftone (tif or eps) 300 dpi. Once the
manuscript has been accepted, figures will be embedded in the text. Location will be selected by the
Journal. Each figure should be cited in the text in parenthesis (Figure 1).
In the description of the Results, do not repeat data from the tables or figures presented. Instead,
emphasize your most relevant findings, especially when tables contain many data or when figures do
not contain quantitative information.
DISCUSSION: This section is critical for judging the relevance of the study. This section should not be
used for repeating the results. Authors should compare their results with other findings previously
reported elsewhere. Authors should also contrast the initial aim of the study to the results.
AUTHORS' PARTICIPATION: Provide a brief description of the role of each author in the study &
manuscript. This Journal does not consider as an author to those who claim to have generated the idea,
reviewed the manuscript, allowed the use of special equipment for the study, provided financial
support, or members of the department without any definitive role in the study or technicians doing
routinely paid work.
ACKNOWLEDGEMENTS: Acknowledge any grant or economical support received. If a person is going to
be acknowledged, it is the authors’ responsibility to grant his/her authorization for publishing the
person’s name.
CONFLICT OF INTERESTS/DISCLAIMERS: Authors are encouraged to disclose any conflict of interest
derived from their commercial relationship with any pharmaceutical company. The decision to publish a
manuscript in the Journal of Experimental & Theoretical Pharmacology will not be affected by the
presence or lack of sponsors. If there is no conflict of interest or disclaimer, the following statement
should be included in this section: None to declare.
References: List a maximum of six authors followed by 'et al.' Journals should be abbreviated according
to the U.S. National Library of Medicine. Examples:
[1] Author A, Author B. The title of the manuscript. J Clin Pharmacol 2007; 47: 1-5.
[2] Author A, Author B, Author C, Author D, Author E, Author F, et al. The title of the manuscript.
Pharmacoepidemiol Drug Saf 2007; 16: 1-15.
[3] Author A. Chapter title. In: Editor A, Editor B. Book title. City, Country: Editorial; 2007: 34-38.
[4] Author A, Author B, Author C. The title of the manuscript. J Clin Pharmacol Pharmacoepidemiol 2007;
1: 10-15 [http://www.journalwebsite.com/PDF/12345].
[5] Author A, Author B, Author C. The title of the manuscript (abstract no. 25). Toxicol Appl Pharmacol
2007; 225.
APPENDIX. Each appendix will be considered by the Editor and the referees in order to evaluate their
relevance for a more in depth understanding of the methods, procedures or equations of the manuscript.
Review papers require a structured abstract, and should summarize the state-of-art of the topic; a
maximum of 100 references are accepted. The final extension of a ‘Review’ should be discussed with the
Editor. For a ‘Letter to the Editor’, no abstract is needed and text should be limited to a maximum of 500
words and a maximum of 5 references. For a ‘Case report’ or a 'Research letter', an abstract of 150
words should be included, followed by a text of maximum 750 words and no more than 10 references.
SUBMISSION AND PUBLICATION FEES
A non-refundable fee of $45.00 Canadian dollars (CAD) will be incurred for all submitted manuscripts.
Once you have submitted the manuscript, we will e-mail to the corresponding author an electronic
receive to be paid with any credit card. If the manuscript is accepted for electronic publication, the
following non-refundable fees (CAD) will be charged: $250 for original articles, $100 for case reports or
case series, and no fee for letters to the Editor. A ‘case report’ or ‘case series’ written as a ‘case report
and review of the literature’, will be invoiced similar to the original articles. There will be no fees for
brief review papers; extensive review articles will be fee similar to an original paper. Inclusion of color
figures will be accepted at a fee of CAD$30 for each figure. There are no fees for B&W figures.
Please submit all correspondence electronically to the Editor.
PremiumReasons this year, 2010.
The Journal welcomes all the spectrum of clinical and epidemiological studies related to drug
development, from phase I to IV, including drug-drug interaction, pharmacokinetic, dose-response,
dose-finding, dose-minimization evaluations, and pharmacoeconomic studies, systematic reviews, meta-
analyses and pharmacovigilance.
Case reports are considered for publication if there is a clear novel contribution to the diagnosis or
treatment of an adverse drug reaction or acute poisoning. Any case report or observational study
reporting maternal and fetal outcomes after first-time unintended exposure to a drug in pregnancy are
welcome. The authors are responsible to present the case report in a form that identification of the
patients is impossible. If authors intend to publish a picture where a patient can be identified, written
informed consent should be obtained from the patient, parents or custodian; its submission to the
journal should also be authorized by the IRB from the center where the case was identified. These forms
should be scanned and attached to the submission of the case report.
The Journal will also consider for publication manuscripts devoted to the analysis of philosophical,
ethical or social aspects of drug research in humans. Only invited review articles will be accepted.
However, authors spontaneously wishing to submit a review paper should first submit an abstract for
consideration.
Letters to the Editor will be accepted for publication when discussing any of the papers previously
published by the Journal in a time not longer than two past issues. A request for reply will be sent to the
authors of the original article. The acceptance of the letter, however, will not be subordinated to the
availability of the authors’ reply.
Research letters containing very preliminary or specific but relevant information in the field of clinical
pharmacology, will be peer reviewed and considered for publication.
Studies should follow local and international norms for the ethical conduct of the clinical trials and be
approved in advance by an IRB. It is unacceptable to submit false studies, duplicated material, or
altered findings. Inclusion of authors who did not participate in the study should be avoided. If any of
the above misconducts are identified by a member of the scientific community and are reported to the
Journal with enough evidence, the Editor will publish in the Journal the details of the authors and the
manuscript involved in the fraudulent submission.
Since the entire submission process is electronic, avoid any postal submission except if the Journal
asks you for a specific document. Authors should adhere to the instructions described below, adapting
the use of headings and subheadings in accordance with submitted papers.
Manuscripts must include a submission letter signed by the corresponding author who declares that the
manuscript has been read and approved by all authors involved in the study; that it has not been
previously published, nor is under consideration elsewhere for publication; and that all the authors have
contributed enough to be considered as coauthors (if more than one author is listed). Grants or sources
of funding as well as any potential conflict of interest should be mentioned in the submission letter.
The submission letter must be scanned and formatted into PDF file format with the signature of the
corresponding author clearly visible. Failure to comply with these requirements may result in the delay
of the review process.
The authors need to provide a signed Copyright Transfer Agreement. The form will be e-mailed to the
corresponding authors together with the acceptance of the manuscript.
The full version of the manuscripts published by the Journal of Clinical Pharmacology &
Pharmacoepidemiology will be available at no cost for academic, personal use. However, the copyright
of all the content will retained by PremiumReasons and authors or any other person interested in further
reproducing the material for commercial or noncommercial use or public dissemination should request
written permission from the publishers (publisher@premiumreasons.com).
Papers will be published in either British or American English.
ABSTRACT. The abstract should be structured into Objectives, Material & Methods, Results, and
Conclusions. The maximum length is 250 words. None or only a minimum of abbreviations should be
used in the abstract. The P values should be preceded by data; use exact P number unless P < 0.001.
Conclusions should be based on the study findings, not on speculations. In order to extend the diffusion
of the manuscripts, abstracts will be published in two more languages, French and Spanish.
KEY WORDS: 3-6 key words should be provided. Use only MeSH terms accepted by the National Library
of Medicine (available through PubMed). If the manuscript contains uncorroborated terms as key words,
the manuscript will be returned to the authors for
correction.
INTRODUCTION: The introduction must be concise but informative, clearly identifying the gap of
knowledge and the aim of the study. All references mentioned in the text must appear in brackets [1]. If
there are several references supporting one comment, only the first and last consecutive numbers
should be written [Example: 2-4]. A maximum of 30 references is permitted for any submitted paper.
Exceptions will be made for review articles or if there is a clear justification for additional references.
SUBJECTS AND METHODS: The first paragraph of this section must specify that the study was
approved by an institutional review board as well as the site where the study was actually performed.
Use the following subheadings: Subjects, Methods, Data analysis. When describing a method that was
previously published elsewhere, cite only the main details of the procedure and include the reference
where the method was described in detail. If a complex or uncommon statistical analysis was
performed, an annotation of the software used or a reference must be provided. For standard statistical
tests do not include any additional description or reference. If the authors are including a set of
equations to support the pharmacological explanation, only the final equation should be included in this
section and the full mathematical model should be submitted as an Appendix.
RESULTS: Authors are encouraged to use text and tables to better present their results. Tables should
be progressively numbered and cited in the results (Table 1). They should be included at the end of the
manuscript following the instructions mentioned below. For values > 1, use only one decimal value, e.g.
1.8, 46.2, 198.5. For values < 1, use two significant decimal values, e.g. 0.76, 0.089, 0.0055. However,
extremely low or extremely high values should be avoided. Instead, data should be expressed in a
different unit. For example, if the mean value is 0.0087 mg dL-1, the value should be better expressed as
8.7 µg dL-1. Similarly, use 87 mg dL-1 instead of 87,000 µg dL-1.
Box plots, when applicable, are preferred over standard figures. However, tables are preferred over
figures. The figures should be submitted as separate files. Image resolutions should be: Line Art (tif or
eps) 800 dpi, Combination (Line Art + Halftone) (tif) 600 dpi, Halftone (tif or eps) 300 dpi. Once the
manuscript has been accepted, figures will be embedded in the text. Location will be selected by the
Journal. Each figure should be cited in the text in parenthesis (Figure 1).
In the description of the Results, do not repeat data from the tables or figures presented. Instead,
emphasize your most relevant findings, especially when tables contain many data or when figures do
not contain quantitative information.
DISCUSSION: This section is critical for judging the relevance of the study. This section should not be
used for repeating the results. Authors should compare their results with other findings previously
reported elsewhere. Authors should also contrast the initial aim of the study to the results.
AUTHORS' PARTICIPATION: Provide a brief description of the role of each author in the study &
manuscript. This Journal does not consider as an author to those who claim to have generated the idea,
reviewed the manuscript, allowed the use of special equipment for the study, provided financial
support, or members of the department without any definitive role in the study or technicians doing
routinely paid work.
ACKNOWLEDGEMENTS: Acknowledge any grant or economical support received. If a person is going to
be acknowledged, it is the authors’ responsibility to grant his/her authorization for publishing the
person’s name.
CONFLICT OF INTERESTS/DISCLAIMERS: Authors are encouraged to disclose any conflict of interest
derived from their commercial relationship with any pharmaceutical company. The decision to publish a
manuscript in the Journal of Experimental & Theoretical Pharmacology will not be affected by the
presence or lack of sponsors. If there is no conflict of interest or disclaimer, the following statement
should be included in this section: None to declare.
References: List a maximum of six authors followed by 'et al.' Journals should be abbreviated according
to the U.S. National Library of Medicine. Examples:
[1] Author A, Author B. The title of the manuscript. J Clin Pharmacol 2007; 47: 1-5.
[2] Author A, Author B, Author C, Author D, Author E, Author F, et al. The title of the manuscript.
Pharmacoepidemiol Drug Saf 2007; 16: 1-15.
[3] Author A. Chapter title. In: Editor A, Editor B. Book title. City, Country: Editorial; 2007: 34-38.
[4] Author A, Author B, Author C. The title of the manuscript. J Clin Pharmacol Pharmacoepidemiol 2007;
1: 10-15 [http://www.journalwebsite.com/PDF/12345].
[5] Author A, Author B, Author C. The title of the manuscript (abstract no. 25). Toxicol Appl Pharmacol
2007; 225.
APPENDIX. Each appendix will be considered by the Editor and the referees in order to evaluate their
relevance for a more in depth understanding of the methods, procedures or equations of the manuscript.
Review papers require a structured abstract, and should summarize the state-of-art of the topic; a
maximum of 100 references are accepted. The final extension of a ‘Review’ should be discussed with the
Editor. For a ‘Letter to the Editor’, no abstract is needed and text should be limited to a maximum of 500
words and a maximum of 5 references. For a ‘Case report’ or a 'Research letter', an abstract of 150
words should be included, followed by a text of maximum 750 words and no more than 10 references.
SUBMISSION AND PUBLICATION FEES
A non-refundable fee of $45.00 Canadian dollars (CAD) will be incurred for all submitted manuscripts.
Once you have submitted the manuscript, we will e-mail to the corresponding author an electronic
receive to be paid with any credit card. If the manuscript is accepted for electronic publication, the
following non-refundable fees (CAD) will be charged: $250 for original articles, $100 for case reports or
case series, and no fee for letters to the Editor. A ‘case report’ or ‘case series’ written as a ‘case report
and review of the literature’, will be invoiced similar to the original articles. There will be no fees for
brief review papers; extensive review articles will be fee similar to an original paper. Inclusion of color
figures will be accepted at a fee of CAD$30 for each figure. There are no fees for B&W figures.
Please submit all correspondence electronically to the Editor.
Editor
Alejandro A. Nava-Ocampo
Toronto, Canada
editor.jcpp@premiumreasons.com
Alejandro A. Nava-Ocampo
Toronto, Canada
editor.jcpp@premiumreasons.com
®